Differences in Sociodemographic Correlates of Human Papillomavirus-Associated Cancer Survival in the United States

Nosayaba Osazuwa-Peters, PhD, BDS, MPH, CHES\(^1\), Matthew C. Simpson, MPH\(^2\), Rebecca L. Rohde, MD, MPH\(^3\), Sai D Challapalli, MD\(^4\), Sean T. Massa, MD\(^5\), and Eric Adjei Boakye, PhD\(^6,7\)

Abstract

**Objectives:** Human papillomavirus (HPV)-associated cancers account for about 9% of the cancer mortality burden in the United States; however, survival differs among sociodemographic factors. We determine sociodemographic and clinical variables associated with HPV-associated cancer survival.

**Methods:** Data derived from the Surveillance, Epidemiology, and End Results 18 cancer registry were analyzed for a cohort of adult patients diagnosed with a first primary HPV-associated cancer (anal, cervical, oropharyngeal, penile, vaginal, and vulvar cancers), between 2007 and 2015. Multivariable Fine and Gray proportional hazards regression models stratified by anatomic site estimated the association of sociodemographic and clinical variables and cancer-specific survival.

**Results:** A total of 77,774 adults were included (11,216 anal, 27,098 cervical, 30,451 oropharyngeal, 2,221 penile, 1,176 vaginal, 5,612 vulvar; average age = 57.2 years). The most common HPV-associated cancer was cervical carcinoma (58%) for females and oropharyngeal (81%) for male. Among patients diagnosed with anal/rectal squamous cell carcinoma (SCC), males had a higher risk of death than females. Non-Hispanic (NH) blacks had a higher risk of death from anal/rectal SCC, oropharyngeal SCC, and cervical carcinoma; and Hispanics had a higher risk of death from oropharyngeal SCC than NH whites. Marital status was associated with risk of death for all anatomic sites except vulvar. Compared to non-Medicaid insurance, patients with Medicaid and uninsured had higher risk of death from anal/rectal SCC, oropharyngeal SCC, and cervical carcinoma.

**Conclusions:** There exists gender (anal) and racial and insurance (anal, cervical, and oropharyngeal) disparities in relative survival. Concerted efforts are needed to increase and sustain progress made in HPV vaccine uptake among these specific patient subgroups, to reduce cancer incidence.

**Keywords**
cancer survival disparities, sociodemographics, human papillomavirus-associated cancers, racial disparities, surveillance, epidemiology, and end results program

\(^1\)Department of Head and Neck Surgery \& Communication Sciences, Duke University School of Medicine, Durham, NC, USA
\(^2\)Department of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine, St Louis, MO, USA
\(^3\)Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, WI, USA
\(^4\)Department of Otorhinolaryngology, Head and Neck Surgery, McGovern Medical School, Houston, TX, USA
\(^5\)Department of Otolaryngology, Head and Neck Surgery, Washington University in Saint Louis School of Medicine, St Louis, MO, USA
\(^6\)Department of Population Science and Policy, Southern Illinois University School of Medicine, Springfield, IL, USA
\(^7\)Simmons Cancer Institute, Southern Illinois University School of Medicine, Springfield, IL, USA

Corresponding Author:
Eric Adjei Boakye, PhD, Southern Illinois University School of Medicine Department of Population Science and Policy 201 E. Madison Street, P. O. Box 19664 Springfield, IL 62794.
Email: eadjeiboakye49@siu.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Eighty million individuals in the United States are currently infected with one or more types of the human papillomavirus (HPV), with 14 million new infections occurring each year. Of the more than 150 HPV types, the nonavalent HPV vaccine covers the major oncogenic types (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58), which are responsible for most of the 44,000 new cases of HPV-associated cancers in the United States annually. These occur in a range of anatomic sites, including the oropharynx, the cervix, and other anogenital sites. These diseases span many medical specialties resulting in research that is often siloed. The incidence of HPV-associated oropharyngeal cancer has dramatically increased, surpassing cervical cancer as the leading HPV-associated cancer in the United States.

HPV-associated cancers account for about 9% of the cancer mortality in the United States; however, survival differs among racial/ethnic groups, and is significantly lower among blacks than whites. Whether significant clinical, biological, or sociodemographic differences underpin these racial differences in survival remains largely inconclusive. Given that eliminating cancer-related racial disparity is a principal objective of the Healthy People 2020 initiative, it is important to understand the clinical/sociodemographic drivers of survival disparity in HPV-associated cancers.

The need to further understand correlates of HPV-associated cancer survival has become even more imperative, as data emerge describing the potential of therapeutic (rather than the current preventive) HPV vaccines. Therapeutic HPV vaccines (when they become available) would likely affect current efforts to reduce if not completely eliminate cervical cancer, responsible for over three-quarters of the global burden of HPV-associated cancers. Unfortunately, current HPV-associated cancer literature is predominated by incidence rather than survival, and primarily for cervical or oropharyngeal cancers, creating a paucity of data on survival of the less prevalent HPV-associated cancers, anal, penile, vaginal, and vulvar malignancies.

The study aimed to determine sociodemographic variables associated with survival in patients diagnosed with HPV-associated cancers. Findings may identify specific, disparate subpopulations at increased risk of death from HPV-associated cancers.

Methods

Data Source

In this retrospective analysis, we used data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) 18 program. SEER is a leading source of population-based information on cancer incidence, staging, and survival, and SEER 18 encompass approximately 27.8% of the United States population. Because SEER is a publicly available database containing de-identified patient information, it was deemed exempt by the Saint Louis University Institutional Review Board.

Patient Population

Patients of 18–99 years diagnosed with a malignant first primary microscopically confirmed HPV-associated cancer were identified from SEER 18 between 2007 and 2015. HPV-associated cancer was defined using the National Program of Cancer Registries’ definition. Six sites were defined by International Classification of Diseases-Oncology (ICD-O)-3 code: anal/rectal squamous cell carcinoma (SCC) (primary sites C20.9, C21.0-C21.8; ICD-O-3 histologic types 8050-8084, 8120-8131), cervical carcinoma (primary sites C53.0-C53.9; histologic types 8010-8671, 8940-8941), oropharyngeal SCC (primary sites C01.9, C02.4, C02.8, C05.1, C05.2, C09.0-C09.9, C10.0-C10.9, C14.0-C14.8), penile SCC (primary sites C60.0-C60.9), vaginal SCC (primary site C52.9), and vulvar SCC (primary sites C51.0-C51.9). Patients were excluded if they did not meet any of the previous criteria, if their cancer was only reported on their death certificate/autopsy, or were alive with no survival time. Also, SEER automatically excludes patients older than 99 for consistency with analyses that use expected survival tables, as these tables for ages 100 and older are unstable.

Measures and Statistical Analysis

The outcome of interest was death from first primary HPV-associated cancer. SEER provides a cause-specific death classification variable that considers patients’ number of tumors, site of first cancer, and comorbidities to reduce cause of death misclassification. SEER also provides patients’ survival time in months from month of diagnosis to month of last contact. Patients who were lost to follow-up or were alive through the last day of database collection were considered censored. Also, by default, SEER®Stat censors patients when they reach 100 years old for consistency with analyses that incorporate expected survival tables.

Sociodemographic variables included in the analyses were sex (female, male), marital status (married/partnered, divorced/separated, never married, unknown, widowed), age at diagnosis (continuous), race/ethnicity (Hispanic (all races), nonHispanic (NH) White, NH Black, NH Asian/Pacific Islander/Native American/Alaska Native (API/AIAN), and insurance type (nonMedicaid insurance; any Medicaid [includes Medicare with Medicaid eligibility]; uninsured; unknown). Clinical factors included anatomic site, stage (I, II, III, IV, unstaged/unknown), surgery (yes, no), radiation (any radiation [beam/nonbeam], no/unknown), and chemotherapy (yes, no/unknown). For radiation and
chemotherapy, SEER does not provide separated values for no and unknown receipt of treatment.17

Preliminary associations between clinical and demographic patient characteristics and overall death were calculated using chi-squared tests and independent samples t-tests where appropriate. Cumulative incidence curves (all-cause death) were created to depict cancer-specific death for each HPV-associated cancer site, stratified by sex for anatomic consistency. Gray’s tests with Bonferroni adjustments were used to determine if significant death existed between each of the 6 sites. We also calculated cumulative incidence curves for each HPV-associated cancer site (cause-specific death) stratified by race/ethnicity, insurance, and stage at presentation (Figures A1, A2, A3 and Table A1). The overall Gray’s test was performed along with comparisons to a predetermined reference group. Multivariable Fine and Gray proportional hazards regression models stratified by anatomic site estimated the association of sociodemographic and clinical variables on cancer-specific death. These associations were estimated using subdistribution hazard ratios (sdHR) and corresponding 95% confidence intervals (CI).

SEER*Stat version 8.3.5 (Surveillance Research Program, National Cancer Institute) was used for data extraction and SAS version 9.4 (SAS Institute, Cary, NC) was used for analyses. Statistical significance was set at P < .05, and all tests were two-tailed.

| Table 1. Characteristics of study sample. | Alive (n = 54 248) | Dead (any cause) (n = 23 526) | Total (n = 77 774) | P-value |
|------------------------------------------|-------------------|------------------------------|-------------------|---------|
| **Age at diagnosis, mean (standard deviation)** | 54.9 (13.1) | 62.3 (14.6) | 57.2 (14.0) | <.01 |
| **Sex, n (%)** | | | | .01 |
| Female | 32 516 (59.9%) | 13 874 (59.0%) | 46 390 (59.7%) | |
| Male | 21 732 (40.1%) | 9652 (41.0%) | 31 384 (40.4%) | |
| **Race/ethnicity, n (%)** | | | | <.01 |
| Hispanic (all races) | 7483 (13.8%) | 2648 (11.3%) | 10 131 (13.0%) | |
| NonHispanic API/AIAN | 3164 (5.8%) | 1199 (5.1%) | 4363 (5.6%) | |
| NonHispanic Black | 4955 (9.1%) | 3601 (15.3%) | 8556 (11.0%) | |
| NonHispanic White | 38 090 (70.2%) | 16 056 (68.3%) | 54 146 (69.6%) | |
| Unknown | 556 (1.0%) | 22 (.1%) | 578 (.7%) | |
| **Marital status, n (%)** | | | | <.01 |
| Divorced/Separated | 7350 (13.6%) | 3969 (16.9%) | 11 319 (14.6%) | |
| Married/Partnered | 27 567 (50.8%) | 8438 (35.9%) | 36 005 (46.3%) | |
| Never married | 12 353 (22.8%) | 6089 (25.9%) | 18 442 (23.7%) | |
| Widowed | 3391 (6.3%) | 3635 (15.5%) | 7026 (9.0%) | |
| Unknown | 3587 (6.6%) | 1395 (5.9%) | 4982 (6.4%) | |
| **Insurance status, n (%)** | | | | <.01 |
| Any Medicaid | 9426 (17.4%) | 5818 (24.7%) | 15 244 (19.6%) | |
| NonMedicaid insurance | 40 336 (74.4%) | 15 314 (65.1%) | 55 650 (71.6%) | |
| Uninsured | 2702 (5.0%) | 1581 (6.7%) | 4283 (5.5%) | |
| Insurance status unknown | 1784 (3.3%) | 813 (3.3%) | 2597 (3.3%) | |
| **Stage, n (%)** | | | | <.01 |
| 0 | 53 (.1%) | 13 (.1%) | 66 (.1%) | |
| I | 16 679 (30.8%) | 2267 (9.6%) | 18 946 (24.4%) | |
| II | 7492 (13.8%) | 2913 (12.4%) | 10 405 (13.4%) | |
| III | 9667 (17.8%) | 5020 (21.3%) | 14 687 (18.9%) | |
| IV | 14 868 (27.4%) | 10 092 (42.9%) | 24 960 (32.1%) | |
| Unstaged/unknown | 5489 (10.1%) | 3221 (13.7%) | 8710 (11.2%) | |
| **Surgery, n (%)** | | | | <.01 |
| Received surgery | 29 047 (53.5%) | 6729 (28.6%) | 35 776 (46.0%) | |
| Did not receive surgery | 24 710 (45.6%) | 16 538 (70.3%) | 41 248 (53.0%) | |
| Unknown | 491 (.9%) | 259 (1.1%) | 750 (1.0%) | |
| **Radiation, n (%)** | | | | .01 |
| Received any radiation (beam/nonbeam) | 35 578 (65.6%) | 15 664 (66.6%) | 51 242 (65.9%) | |
| No/unknown radiation | 18 670 (34.4%) | 7862 (33.4%) | 26 532 (34.1%) | |
| **Chemotherapy, n (%)** | | | | <.01 |
| Yes | 30 841 (56.9%) | 13 828 (58.8%) | 44 669 (57.4%) | |
| No/Unknown | 23 407 (43.2%) | 9698 (41.2%) | 33 105 (42.6%) | |
Results

Table 1 summarizes the characteristics of study patients. A total of 77,774 adult patients with a first primary HPV-associated cancer diagnosed from 2007 to 2015 were included. Patients’ average age was 57.2 years. For females, the most common HPV-associated cancer was cervical carcinoma (58%), and for males the most common HPV-associated cancer was oropharyngeal SCC (81%, Table 2). Overall survival rate at the end of the 8-year follow-up was 54%.

There were significant differences in cancer-specific death based on anatomic site for both males and females (Gray’s test P < .01). For females, vaginal SCC had the highest cancer-specific cumulative death (46%) compared with oropharyngeal SCC (37%), cervical carcinoma (32%), vulvar SCC (31%), and anal/rectal SCC (24%) [Bonferroni P < .05, Figure 1]. For males, penile SCC had the lowest cancer-specific cumulative death (26%) compared to anal/rectal SCC (32%) and oropharyngeal SCC (32%), while there was no significant difference between anal/rectal SCC and oropharyngeal SCC (Bonferroni P < .05, Figure 2).

After using the multivariable competing risks proportional hazards model to adjust for clinical and nonclinical factors, significant sociodemographic differences persisted in cancer-specific death among patients with HPV-associanted cancers (Table 3). For all HPV-associated cancers, older age at diagnosis was associated with increased cancer-specific death. Males with anal/rectal SCC were 62% more likely to die than females (sdHR = 1.62, 95% CI 1.47, 1.78), but for oropharyngeal SCC, males were 8% less likely to die (sdHR = .92, 95% CI 0.86, .98). Compared to NH whites, Hispanics had 23% increased risk of death from oropharyngeal SCC (sdHR = 1.23, 95% CI 1.13, 1.35) but 14% decreased mortality from cervical carcinoma (sdHR = .86, 95% CI 0.81, .93); NH API/AIAN had 12% decreased risk of death from cervical carcinoma (sdHR = .88, 95% CI 0.81, .97); and NH blacks had increased risk of death from anal/rectal SCC, oropharyngeal SCC, and cervical carcinoma but had 25% decreased risk of death from vulvar SCC (sdHR = .75, 95% CI 0.59, .95).

Compared to married/partnered patients, divorced/separated patients had 46% increased risk of death from oropharyngeal SCC (sdHR = 1.46, 95% CI 1.36, 1.56) and 18% increased risk of death from cervical carcinoma (sdHR = 1.18, 95% CI 1.09, 1.27); never married patients had 24% increased risk of death from anal/rectal SCC (sdHR = 1.24, 95% CI 1.21, 95% CI 1.30), and 35% increased risk of death from vulvar SCC (sdHR = 1.35, 95% CI 1.30, 1.35) but 14% decreased mortality from cervical carcinoma (sdHR = .86, 95% CI 0.81, .93); NH API/AIAN had 12% decreased risk of death from cervical carcinoma (sdHR = .88, 95% CI 0.81, .97); and NH blacks had increased risk of death from anal/rectal SCC, oropharyngeal SCC, and cervical carcinoma but had 25% decreased risk of death from vulvar SCC (sdHR = .75, 95% CI 0.59, .95).

Compared to nonMedicaid insurance patients, patients with any Medicaid had 46% increased risk of death from oropharyngeal SCC (sdHR = 1.46, 95% CI 1.36, 1.56) and 18% increased risk of death from cervical carcinoma (sdHR = 1.18, 95% CI 1.09, 1.27) and 10% increased risk of death from cervical carcinoma (sdHR = 1.10, 95% CI 1.04, 1.17), 10% increased risk of death from oropharyngeal SCC (sdHR = 1.79, 95% CI 1.67, 1.91), and 23% increased mortality from vulvar SCC (sdHR = 1.23, 95% CI 1.04, 1.45). Also, compared to nonMedicaid insurance patients, uninsured patients had 71% increased risk of death from anal/rectal SCC (sdHR = 1.71, 95% CI 1.44, 2.04), 73% increased risk of death

| Table 2. HPV-associated cancer sites by sex. |
|---------------------------------------------|
|                                     | Female |                                      | Male |
|                                     | Alive  | Dead (any cause) | Total | Alive | Dead (any cause) | Total | P-value |
|                                   | (n = 32,516) | (n = 13,874) | (n = 46,390) | (n = 21,732) | (n = 9,652) | (n = 31,384) |  <.01 | <.01  |
| HPV-associated cancer              |        |                |       |       |                |       |         |
| Anal and rectal squamous cell carcinoma | 5427 (16.7%) | 1910 (13.8%) | 7337 (15.8%) | 2555 (11.8%) | 1324 (13.7%) | 3879 (12.4%) |       |
| Cervical carcinoma                 | 19,492 (60.0%) | 7606 (54.8%) | 27,098 (58.4%) | — | — | — |  <.01 |
| Oropharyngeal squamous cell carcinoma | 3252 (10.0%) | 1915 (13.8%) | 5167 (11.1%) | 17,739 (81.6%) | 7545 (78.2%) | 25,284 (80.6%) |       |
| Penile squamous cell carcinoma     | — | — | — | 1438 (6.6%) | 783 (8.1%) | 2221 (7.1%) |       |
| Vaginal squamous cell carcinoma    | 616 (1.9%) | 560 (4.0%) | 1176 (2.5%) | — | — | — |       |
| Vulvar squamous cell carcinoma     | 3729 (11.5%) | 1883 (13.6%) | 5612 (12.1%) | — | — | — |       |
Figure 1. Cumulative incidence curves (outcome = cancer-specific death) of female study population by primary cancer site. SCC: Squamous cell carcinoma.

Figure 2. Cumulative incidence curves (outcome = cancer-specific death) of male study population by primary cancer site. SCC: Squamous cell carcinoma.
Table 3. Competing risks proportional hazards regression results

| Both sexes | Oropharyngeal SCC | Female sites | Cervical carcinoma | Vaginal SCC | Vulvar SCC | Male sites | Penile SCC |
|------------|-------------------|-------------|-------------------|------------|-----------|------------|-----------|
|            | Anal/rectal SCC   |             |                   |            |           |            |           |
|            | sdHR 95% CI       | sdHR 95% CI | sdHR 95% CI       | sdHR 95% CI | sdHR 95% CI | sdHR 95% CI | sdHR 95% CI |
| Age at diagnosis (continuous) | 1.02 1.02, 1.03 | 1.03 1.03, 1.04 | 1.01 1.01, 1.01 | 1.02 1.01, 1.03 | 1.03 1.03, 1.04 | 1.01 1.00, 1.02 |
| Year of diagnosis (continuous) | .96 .94, .98 | .96 .95, .97 | .98 .97, .99 | .95 .91, .99 | .98 .96, 1.01 | .96 .92, 1.00 |
| Sex (reference = female) | Male | 1.62 1.47, 1.78 | .92 .86, .98 | — — | — — | — — | — — |
| Race/ethnicity (reference = nonHispanic White) | Hispanic (all races) | 1.23 1.13, 1.35 | .86 .81, .93 | .97 .72, 1.31 | .98 .79, 1.22 | .84 .65, 1.09 |
|            | Non-Hispanic API/AIAN | 1.13 .99, 1.29 | .88 .81, .97 | .96 .60, 1.54 | .90 .64, 1.25 | .66 .42, 1.04 |
|            | Non-Hispanic Black | 1.28 1.12, 1.46 | 1.55 1.44, 1.67 | 1.11 1.03, 1.19 | .99 .73, 1.35 | .75 .59, .95 | 1.18 .84, 1.65 |
| Marital status (reference = married/partnered) | Divorced/Separated | 1.12 .98, 1.28 | 1.46 1.36, 1.56 | 1.18 1.09, 1.27 | 1.06 .79, 1.44 | .97 .79, 1.18 | 1.03 .75, 1.40 |
|            | Never married | 1.24 1.10, 1.39 | 1.51 1.41, 1.61 | 1.21 1.13, 1.30 | .93 .68, 1.26 | 1.10 .91, 1.33 | 1.35 1.03, 1.76 |
|            | Widowed | 1.36 1.16, 1.58 | 1.45 1.31, 1.60 | 1.07 .97, 1.18 | .89 .67, 1.19 | .99 .84, 1.17 | 1.37 1.00, 1.92 |
|            | Unknown | 1.00 .81, 1.23 | 1.08 .96, 1.21 | 1.02 .90, 1.16 | .55 .32, .93 | 1.00 .76, 1.31 | 1.26 .79, 2.02 |
| Insurance status (reference = nonMedicaid insurance) | Any Medicaid | 1.46 1.30, 1.64 | 1.79 1.67, 1.91 | 1.10 1.04, 1.17 | 1.18 .91, 1.54 | 1.23 1.04, 1.45 | 1.20 .90, 1.59 |
|            | Uninsured | 1.71 1.44, 2.04 | 1.73 1.56, 1.91 | 1.14 1.03, 1.25 | 2.03 1.26, 3.25 | 1.32 .94, 1.84 | 1.15 .76, 1.72 |
|            | Insurance status unknown | .91 .69, 1.21 | 1.12 .95, 1.31 | .89 .75, 1.05 | 1.20 .69, 2.07 | .95 .67, 1.35 | .84 .48, 1.47 |
| Stage (reference = I) | II | 1.65 1.38, 1.99 | 1.46 1.19, 1.79 | 3.38 2.96, 3.86 | 1.83 1.29, 2.61 | 2.27 1.78, 2.89 | 2.66 1.99, 3.56 |
|            | III | 3.29 2.74, 3.94 | 2.07 1.73, 2.49 | 6.69 5.94, 7.55 | 2.45 1.70, 3.54 | 4.79 3.73, 6.16 | 3.66 2.73, 4.91 |
|            | IV | 10.21 8.42, 12.39 | 3.22 2.70, 3.83 | 17.22 15.30, 19.39 | 5.82 4.09, 8.29 | 10.17 7.77, 13.33 | 8.00 5.70, 11.21 |
|            | Unstaged/unknown | 1.90 1.58, 2.28 | 2.34 1.95, 2.80 | 4.74 4.14, 5.43 | 2.56 1.65, 3.97 | 2.79 2.16, 3.60 | 2.99 2.01, 4.45 |
| Surgery (reference = did not receive surgery) | Received surgery | .67 .60, .75 | .49 .46, .52 | .49 .42, .48 | .45 .33, .61 | .41 .35, .47 | .50 .37, .67 |
| Radiation (reference = no/unknown radiation) | Received any radiation (beam/nonbeam) | .71 .62, .82 | .41 .38, .44 | .81 .75, .88 | .82 .63, 1.08 | 1.20 1.00, 1.44 | 1.09 .80, 1.48 |
| Chemotherapy (reference = no/unknown chemotherapy) | Received chemotherapy | .68 .59, .78 | .83 .78, .89 | .75 .69, .81 | .80 .63, 1.02 | .82 .69, .98 | 1.65 1.25, 2.18 |

SCC = squamous cell carcinoma; sdHR = subdistribution hazard ratios; CI = confidence interval; bold values are statistically significant at P < .05.
from oropharyngeal SCC (sdHR = 1.73, 95% CI 1.56, 1.91), 14% increased risk of death from cervical carcinoma (sdHR = 1.14, 95% CI 1.03, 1.25), and 103% increased risk of death from vaginal SCC (sdHR = 2.03, 95% CI 1.26, 3.25).

The multivariable models showed that for all HPV-associated cancer sites, stages II, III, and IV cancers had significantly increased cancer-specific death than stage I cancer. Also, patients who received surgery for all cancer sites had significantly decreased cancer-specific death than those who did not. Receiving any radiation (beam/nonbeam) was associated with significantly decreased cancer-specific death from anal/rectal SCC (sdHR = .71, 95% CI 0.62, .82), oropharyngeal SCC (sdHR = .41, 95% CI 0.38, .44), and cervical SCC (sdHR = .81, 95% CI 0.75, .88) compared to no/unknown radiation. Receiving chemotherapy was associated with significantly decreased cancer-specific death from anal/rectal SCC (sdHR = .68, 95% CI 0.59, .78), oropharyngeal SCC (sdHR = .83, 95% CI 0.78, .89), cervical SCC (sdHR = .75, 95% CI 0.69, .81), and vulvar SCC (sdHR = .82, 95% CI 0.69, .98) but was associated with significantly increased cancer-specific death from penile SCC (sdHR = 1.65, 95% CI 1.25, 2.18).

**Discussion**

Several previous SEER-based studies have examined prognostic factors related to survival of HPV-associated cancers, however most have focused on cervical and oropharyngeal cancer, and less so on rarer types of HPV-associated malignancies. Recently, Razzaghi et al used 27 population-based cancer registries to assess the role of age, race, and gender on survival of HPV-associated cancer, but their study was mostly descriptive, and their data excluded marital status and insurance status. Our study examined survival outcomes of all HPV-associated cancers based on sociodemographic factors and build on the Razzaghi et al study. For a group of cancers with known survival disparity, social support, and health care access are well known patient variables predicting prognosis, and are integral for inclusion in cancer survival modeling.
Our study found an overall survival rate of 54% at the end of follow-up. Razzaghi et al., who reported 5-year survival rates ranging from as low as 47.4% (penile) to as high as 66% (vulvar), depending on primary cancer site. Considering 90% of anal and cervical cases are attributable to HPV types for which there is the nonavalent vaccine, a dramatic reduction in incidence should be achievable through primary prevention. In Australia, a recent disease modeling study revealed that the nation was on track to eliminate cervical cancer as a major public health threat by 2028, in part due to a highly successful HPV vaccination campaign. The United States is similarly positioned to achieve such cancer prevention milestones, but success is largely contingent upon the ability to improve current HPV vaccination strategies and increase uptake rates. It should be noted that individuals affected by HIV are disproportionately affected by HPV-associated cancers. For instance, a study found that although HIV-associated infections seemed to contribute minimally to the excess risk of death for women with HPV-associated cancers, women with HIV have a rapid progression of cervical cancer compared to HIV-uninfected women. Similarly, survival among individuals with anal cancer is influenced by their HIV status especially among men with HIV.

We found gender disparities in survival of HPV-associated oropharyngeal and anal cancers. Interestingly, these HPV-associated cancers that occur in both sexes have continued to increase in incidence over the last two decades. Previous studies have been inconclusive about gender differences in survival of oropharyngeal cancer. In the current study, males had a significantly elevated risk of death from anal cancer, but lower risk of death from oropharyngeal cancer, which is broadly consistent with the recent findings from Razzaghi and colleagues. The lack of consensus in the literature highlights the need for studies that explore factors related to gender differences in cancer survival outcomes, including tumor biology, inequities in health care access, and risks from other competing causes of death.

The potential impact of health insurance on survival was evidenced among low-income individuals with Medicaid or uninsured, particularly for patients with anal or oropharyngeal cancer. Notably, those with Medicaid experienced worse survival outcomes than those with private coverage, particularly among oropharyngeal cancer patients. Individuals

**Figure A2.** Cumulative incidence curves for cancer-specific mortality stratified by insurance status for each HPV-related cancer site. Anal/rectal squamous cell carcinoma (SCC) overall Gray’s test $p < 0.01$; comparisons to non-Medicaid insurance: any Medicaid $p < 0.01$, insurance status unknown $p = 0.76$, uninsured $p < 0.01$. Cervical carcinoma overall Gray’s test $p < 0.01$; comparisons to non-Medicaid insurance: any Medicaid $p < 0.01$, insurance status unknown $p = 0.47$, uninsured $p < 0.01$. Oropharyngeal SCC overall Gray’s test $p < 0.01$; comparisons to non-Medicaid insurance: any Medicaid $p < 0.01$, insurance status unknown $p < 0.01$, uninsured $p < 0.01$. Penile SCC overall Gray’s test $p = 0.01$; comparisons to non-Medicaid insurance: any Medicaid $p < 0.01$, insurance status unknown $p = 0.39$, uninsured $p = 0.17$. Vaginal SCC overall Gray’s test $p = 0.01$; comparisons to non-Medicaid insurance: any Medicaid $p = 0.01$, insurance status unknown $p = 0.35$, uninsured $p = 0.02$. Vulvar SCC overall Gray’s test $p = 0.11$; comparisons to non-Medicaid insurance: any Medicaid $p = 0.15$, insurance status unknown $p = 0.78$, uninsured $p = 0.07$. Cancer Control
enrolled in Medicaid tend to be less healthier than those who are uninsured or privately insured—they experience a greater burden of health comorbidities due to generally lower socioeconomic status and higher rates of unemployment. Oftentimes, individuals who suffer from a serious health event or disabling illness who should be the first to seek coverage do so retroactively rather than enrolling prior to health detriment, in a phenomenon known as adverse selection. In some patients, some patients may only qualify for Medicaid after a late stage diagnosis, or in some cases, after being admitted for cancer treatment. These individuals are likely to sustain worse oncologic survival outcomes compared to their privately insured counterparts. Interestingly, there seems to be a complex interplay between health insurance status, stage of presentation, and race, and in the current study, blacks, who were also more likely to be uninsured or under Medicaid, were more likely to die from their HPV-associated cancers. While studies have attempted to describe racial differences in cancer outcomes according to racial differences in tumor biology and treatment responses, most have concluded that stage of presentation and unequal access to quality cancer care play a greater role in cancer health disparities than do biological and tumor characteristics. Racial/ethnic minorities should be the target of future HPV-associated cancer interventions, since this population may likely continue to suffer worse outcomes if barriers to health care access are not addressed. Interestingly, marriage positively impacted survival after penile, anal, and oropharyngeal cancers—all male-related HPV-associated cancers. In fact, unmarried patients with penile and oropharyngeal cancers had the most dramatic association with marital status (in both genders and across all HPV-associated cancers). However, among the female-only HPV-associated cancers, only cervical cancer had a statistically significant difference between the married and unmarried survivors. There is evidence that among cancer survivors, males might benefit from being married more than females. Marriage may be a proxy

Table A1. Among cervical carcinoma patients, stage at presentation by age group.

|        | I (n = 12,629) | II (n = 3,516) | III (n = 5,689) | IV (n = 3,870) | Unstaged/unknown (n = 1,394) | Total (n = 27,098) |
|--------|----------------|----------------|-----------------|----------------|-----------------------------|-------------------|
| 18-29  | 1,060 (66.4%)  | 93 (5.8%)      | 269 (16.8%)     | 87 (5.5%)      | 88 (5.5%)                   | 1,597 (5.9%)      |
| 30-65  | 10,429 (48.9%) | 2,624 (12.3%)  | 4,462 (20.9%)   | 2,863 (13.4%)  | 956 (4.5%)                  | 21,334 (78.7%)    |
| 66 and older | 1,140 (27.4%) | 799 (19.2%)    | 958 (23.0%)     | 920 (22.1%)     | 350 (8.4%)                  | 4,167 (15.4%)     |

Figure A3. Cumulative incidence curves for cancer-specific mortality stratified by stage at presentation for each HPV-related cancer site. For all sites, the overall Gray’s test $p < 0.01$, and comparisons to stage I $p < 0.01$. 

Table A1. Among cervical carcinoma patients, stage at presentation by age group.
measure for social support, which is critical among cancer survivors due to the huge psychosocial burden of cancer survivorship. It is therefore important to seek that better understanding of optimal support for these survivors. Critically, among sexual minorities, the impact of same-sex marriage on marital support deserves more attention, especially for oropharyngeal and anal cancers which have well-documented associations with sexual lifestyle and preferences.

Limitations and Strengths

This study has important limitations. First, SEER files used for this study do not contain information on HPV-DNA tumor status, so cancers were classified based solely on histologic examination, or anatomic proxy (for HPV-associated oropharyngeal cancer). This introduces the potential for misclassification of etiologically associated HPV cancers as non-HPV-associated cancers (or vice versa), leading to biased results. For example, in oropharyngeal cancer where HPV-association has strong prognostic implications, some of the observed survival disparities may be explained by unmeasured differences in rates of HPV-associated tumors. Second, data on comorbidities was unavailable and therefore we were unable to control for them and these might affect our study findings. However, by focusing on cancer-specific mortality the impact of death directly from comorbid disease should be minimized. Third, other risk factors, such as tobacco use, might impact survival of HPV-associated cancers, especially oropharyngeal cancer, but we were unable to control for this with the data available.

Notwithstanding these limitations, this is the first study of its kind to examine the association between marital status and health insurance status with survival of HPV-associated cancers in the United States and to assess cancer-specific survival on a population level across HPV-associated cancer sites. By design, the population-based nature of this study is an added strength, offering access to diverse population-level data and increased generalizability of our findings.

Clinical and Public Health Implications

As the number of HPV-associated cancer survivors continues to grow, a call to action for greater cancer survivorship surveillance is warranted. While the preventable nature of most HPV-associated cancers cannot be overstated, the lasting impact of HPV vaccination programs and screenings in potentially eliminating HPV-associated cancers hinges on concerted efforts to increase and sustain progress made in HPV vaccine uptake. In 2019, 71.5% of adolescents aged 13–17 years received ≥1 dose of HPV vaccine (73.2% for girls and 69.8% for boys) and 54.2% completed the series (56.8% for girls and 51.8% for boys). For young adults aged 18–26 years, this uptake is even lower, with national initiation rates of 40% for women and only 8% for men. Recent news that vaccine coverage will include individuals through 27–45 years implies that millions of people who were previously deemed ineligible may qualify to receive the HPV vaccine in the future. This new HPV vaccine-eligible age range coincides with the increased shift towards HPV-associated cancer among younger adults less than 50 years. Furthermore, because of the delay from HPV infection to cancer diagnosis, there is a large age cohort at risk who missed window for the preventative vaccination. These patients are reliant on early diagnosis and treatment, which our study highlights still have large disparities. Our study provides additional support for targeted policy interventions addressing expanding health care access to help reduce health outcome disparities. Future studies may also explore the interaction of demographic and clinical characteristics on cancer-specific survival. Examples include determining if the associations of stage and treatment with cancer-specific survival are different based on marital status or insurance status, as patients who are unmarried or of lower socioeconomic status may have increased benefit of early stage at presentation or receiving treatment on their cancer-specific survival than those with better social support or of higher socioeconomic status.

Conclusion

We found marked sociodemographic disparities in HPV-associated cancer survival in the United States that often transcend specific sites. It is important that factors associated with survival, including the nonclinical factors described in this study, continue to be evaluated. In particular, the need for equal access to high-quality cancer care independent of race or health insurance status remains. Cancer survivors will continue to need social and emotional support as they progress in their cancer survivorship journey.

Author Note

Abstract of this paper was presented at the 2018 AACR Annual Meeting, Chicago, IL.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical Approval

Ethical review and approval was not required for the study because a publicly available data was used.
References

1. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2008;40(3):187-193.

2. Chung CH, Bagheri A, D’Souza G. Epidemiology of oral human papillomavirus infection. Oral Oncology. 2014;50(5):364-369.

3. Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086.

4. Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in human papillomavirus-associated cancers - United States, 1999-2015. MMWR. Morbidity and Mortality Weekly Report. 2018;67(33):918-924.

5. Osazuwa-Peters N, Massa ST, Simpson MC, Adjei Boakye E, Varvares MA. Survival of human papillomavirus-associated cancers: filling in the gaps. Cancer. 2018;124(1):18-20.

6. Razzaghi H, Saraiya M, Thompson TD, Henley SJ, Viens L, Wilson R. Five-year relative survival for human papillomavirus-associated cancer sites. Cancer. 2018;124(1):203-211.

7. U.S. Department of Health and Human Services. Healthy People, 2020. https://www.healthypeople.gov/2020/topics-objectives/2020-Topics-and-Objectives-Objectives-A-Z

8. Massarelli E, William W, Johnson F, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer: a phase 2 clinical trial. JAMA Oncology. 2018;5(1):67-73.

9. Dadar M, Chakraborty S, Dhamka K, et al. Advances in designing and developing vaccines, drugs and therapeutic approaches to counter human papilloma virus. Front Immunol. 2018;9:2478.

10. Harper DM, Nieminen P, Donders G, et al. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5years of follow-up. Gynecol Oncol. 2019;153:521-529.

11. Simms KT, Steinberg J, Curana M, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. Lancet Oncol. 2019;20(3):394-407.

12. Shielis MS, Kreimer AR, Coghill AE, Darragh TM, Devesa SS. Anal cancer incidence in the United States, 1977-2011: distinct patterns by histology and behavior. Cancer Epidemiol Biomark Prev. 2015;24(10):1548-1556.

13. Wright JD, Chen L, Tergas AI, et al. Population-level trends in relative survival for cervical cancer. Am J Obstet Gynecol. 2015;213(5):670-677.

14. Viens LJ. Human Papillomavirus–Associated cancers—United States, 2008–2012. MMWR Morbidity and mortality weekly report; 2016:65.

15. Goodman MT, Saraiya M, Thompson TD, et al. Human papillomavirus genotype and oropharynx cancer survival in the United States of America. Eur J Cancer. 2015;51(18):2759-2767.

16. Tota JE, Best AF, Zumsteg ZS, Gillison ML, Rosenberg PS, Chaturvedi AK. Evolution of the oropharynx cancer epidemic in the United States: moderation of increasing incidence in younger individuals and shift in the burden to older individuals. J Clin Oncol : Official Journal of the American Society of Clinical Oncology. 2019;37(19):1900370.

17. Incidence - SEER 18 Regs Custom Data (With Additional Treatment Fields), Nov 2017 Sub (2000-2015) <Katrina/Rita population adjustment> - linked to county attributes - Total U.S., 1969-2016 Counties. In: National Cancer Institute D, Surveillance Research Program, ed2018.

18. Overview of the SEER Program. National Cancer Institute. https://seer.cancer.gov/about/overview.html. 2018. Accessed November 3, 2018.

19. SEER*Stat Databases: November 2017 Submission. National Cancer Institute. https://seer.cancer.gov/data/seerstat/nov2017/. Accessed June 19, 2018.

20. Institute NC. NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Database Data Standards and Data Dictionary; 2018. https://www.cdc.gov/cancer/uscs/public-use/pdf/npcr-seer-public-use-database-data-dictionary-2001-2015-508.pdf Accessed April 1, 2019.

21. Institute NC. Expected Survival Life Tables. https://seer.cancer.gov/expsurvival/. Accessed January 22, 2021.

22. Haines ER, Frost AC, Kane HL, Rokoske FS. Barriers to accessing palliative care for pediatric patients with cancer: a review of the literature. Cancer. 2018;124(11):2278-2288.

23. Osta BE, Palmer JL, Paraskevopoulos T, et al. Interval between first palliative care consult and death in patients diagnosed with advanced cancer at a comprehensive cancer center. J Palliat Med. 2008;11(1):51-57.

24. Kassa H, Murugaran R, Zewdu F, Hailu M, Woldeyohannes D. Assessment of knowledge, attitude and practice and associated factors towards palliative care among nurses working in selected hospitals, Addis Ababa, Ethiopia. BMC Palliative Care. 2014;13(1):6.

25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.

26. Shiels MS, Kreimer AR, Coghill AE, Darragh TM, Devesa SS. Anal Cancer Incidence in the United States, 1977-2011: Distinct Patterns by Histology and Behavior. Cancer Epidemiology and Prevention Biomarkers; 2015. cebp. 0044.

27. Ell K, Nishimoto R, Mediansky L, Mantell J, Hamovitch M. Social relations, social support and survival among patients with cancer. J Psychosom Res. 1992;36(6):531-541.

28. Markt SC, Tang T, Cronin AM, et al. Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival. PLoS One. 2018;13(2):e0193047.
29. Kwok J, Langevin SM, Argiris A, Grandis JR, Gooding WE, Taioli E. The impact of health insurance status on the survival of patients with head and neck cancer. *Cancer*. 2010;116(2):476-485.
30. Hall MT, Simms KT, Lew J-B, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. The Lancet Public Health; 2018.
31. Jacobson RM, Agunwamba AA, St Sauver JL, Finney Rutten LJ. The most effective and promising population health strategies to advance human papillomavirus vaccination. *Expert Rev Vaccine*. 2016;15(2):257-269.
32. Cubie HA, Seagar AL, Beattie GJ, Monaghan S, Williams ARW. A longitudinal study of HPV detection and cervical pathology in HIV infected women. *Sex Transm Infect*. 2000;76(4):257-261.
33. Beachler DC, Weber KM, Margolick JB, Strickler HD, Cranston RD, Burk RD, et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. *Cancer Epidemiol Biomark Prev*; 2012; 21(1):122-133.
34. Dryden-Peterson S, Bvochora-Nsingo M, Suneja G, et al. HIV infection and survival among women with cervical cancer. *J Clin Oncol*. 2016;34(31):3749-3757.
35. Lin BM, Wang H, D’Souza G, et al. Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. *Cancer*. 2013;119(19):3462-3471.
36. Tiwana MS, Wu J, Hay J, Wong F, Cheung W, Olson RA. 25 year survival outcomes for squamous cell carcinomas of the head and neck: population-based outcomes from a Canadian province. *Oral Oncol*. 2014;50(7):651-656.
37. Osazuwa-Peters N, Massa ST, Christopher KM, Walker RJ, Varvares MA. Race and sex disparities in long-term survival of oral and oropharyngeal cancer in the United States. *J Cancer Res Clin Oncol*. 2016;142(2):521-528.
38. Holahan J, Kenney G, Pelletier J. The Health Status of New Medicaid Enrollees under Health Reform. Urban Institute; 2010.
39. Cutler DM, Zeckhauser RJ. Adverse selection in health insurance. Paper presented at: Forum for Health Economics & Policy 1998.
40. Osazuwa-Peters N, Christopher KM, Hussaini AS, Behera A, Walker RJ, Varvares MA. Predictors of stage at presentation and outcomes of head and neck cancers in a university hospital setting. *Head Neck*. 2016;38(Suppl 1):E1826-E1832.
41. Bradley CJ, Gardiner J, Given CW, Roberts C. Cancer, medicaid enrollment, and survival disparities. *Cancer*. 2005;103(8):1712-1718.
42. Osazuwa-Peters N, Adjei Boakye E, Chen BY, Tobo BB, Varvares MA. Association between head and neck squamous cell carcinoma survival, smoking at diagnosis, and marital status. *JAMA otolaryngology– head & neck surgery*. 2018;144(1):43-50.
43. Gourin CG, Podolsky RH. Racial disparities in patients with head and neck squamous cell carcinoma. *Laryngoscope*. 2006;116(7):1093-1106.
44. Sheppard CS, El-Zein M, Ramanakumar AV, Ferencyz A, Franco EL. Assessment of mediators of racial disparities in cervical cancer survival in the United States. *Int J Cancer*. 2016;138(11):2622-2630.
45. Simpson MC, Challapalli SD, Cass LM, et al. Impact of gender on the association between marital status and head and neck cancer outcomes. *Oral Oncology*. 2019;89:48-55.
46. Rohde RL, Adjei Boakye E, Challapalli SD, et al. Prevalence and sociodemographic factors associated with depression among hospitalized patients with head and neck cancer-Results from a national study. *Psycho Oncol* 2018;27(12):2809-2814.
47. Osazuwa-Peters N, Simpson MC, Zhao L, et al. Suicide risk among cancer survivors: head and neck versus other cancers. *Cancer*. 2018;124(20):4072-4079.
48. Adjei Boakye E, Osazuwa-Peters N, Mohammed KA, et al. Prevalence and factors associated with diagnosed depression among hospitalized cancer patients with metastatic disease. *Soc Psychiatr Psychiatr Epidemiol*. 2020;55(1):15-23.
49. D’Souza G, Cullen K, Bowie J, Thorpe R, Fakhry C. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. *PloS One*. 2014;9(1):e86023.
50. Prendes BL, Wang SJ, Groppo ER, Eisele DW, Palefsky JM. Oral human papillomavirus infection in men who have sex with men with anal squamous intraepithelial lesions. *Head Neck*. 2016;38(Suppl 1):E399-E405.
51. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. *Lancet Oncol*. 2012;13(5):487-500.
52. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. *J Clin Oncol*. 2012;30(17):2102-2111.
53. Elam-Evans LD, Yankey D, Singleton JA, et al. National, regional, and state, and selected local area vaccination coverage among adolescents aged 13-17 Years - United States, 2019. *MMWR. Morbidity and Mortality Weekly Report*. 2020;69(33):1109-1116.
54. Adjei Boakye E, Lew D, Muthukrishnan M, et al. Correlates of human papillomavirus (HPV) vaccination initiation and completion among 18-26 year olds in the United States. *Hum Vaccines Immunother*. 2018;14(8):2016-2024.
55. US Food and Drug Administration (FDA). FDA Approves Expanded Use of Gardasil 9 to Include Individuals 27 through 45 Years Old; 2018. <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622715.htm>
56. Osazuwa-Peters N, Simpson MC, Massa ST, Adjei Boakye E, Antisdel JL, Varvares MA. 40-year incidence trends for oropharyngeal squamous cell carcinoma in the United States. *Oral Oncol*. 2017;74(suppl C):90-97.
57. Tota JE, Best AF, Zumsteg ZS, Gillison ML, Rosenberg PS, Chaturvedi AK. Evolution of the oropharynx cancer epidemic in the United States: moderation of increasing incidence in younger individuals and shift in the burden to older individuals. *J Clin Oncol*. 2019;37(18):1538-1546.